AecorBio Inc. is a US-based biotechnology company specializing in the development of innovative bioactive peptides for therapeutic use in oncology, inflammatory, and autoimmune diseases. The company's proprietary peptide platform has yielded multiple drug candidates, with its lead candidate, FT-002a, targeting advanced prostate cancer. AecorBio's approach involves modulating tumor iron metabolism to enhance treatment efficacy. Supported by a strong intellectual property portfolio and global academic collaborations, AecorBio is advancing a multi-asset pipeline aimed at addressing significant unmet medical needs.
Leadership & Board
Currently, no data available
Latest Estimated Valuation
Estimated Valuation$30M
Estimated Valuation$30M
Total Amount Raised$2M
Total Amount Raised$2M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$2M
Latest Funding Amount$2M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation$30M
Post-Money Valuation$30M
Funding Round
Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Sep 17, 2025
Investment
$1.50M
$30.00M
Similar Companies
A snapshot of private companies similar to AecorBio Inc, helping you discover and navigate related company profiles.